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Abstract
The TLR7 agonist imiquimod has been used successfully as adjuvant for skin treatment of virus-associated warts and basal
cell carcinoma. The effects of skin TLR7 triggering on respiratory leukocyte populations are unknown. In a placebo-
controlled experimental animal study we have used multicolour flow cytometry to systematically analyze the modulation of
respiratory leukocyte subsets after skin administration of imiquimod. Compared to placebo, skin administration of
imiquimod significantly increased respiratory dendritic cells (DC) and natural killer cells, whereas total respiratory leukocyte,
alveolar macrophages, classical CD4+ T helper and CD8+ T killer cell numbers were not or only moderately affected. DC
subpopulation analyses revealed that elevation of respiratory DC was caused by an increase of respiratory monocytic DC
and CD11bhi DC subsets. Lymphocyte subpopulation analyses indicated a marked elevation of respiratory natural killer cells
and a significant reduction of B lymphocytes. Analysis of cytokine responses of respiratory leukocytes after stimulation with
Klebsiella pneumonia indicated reduced IFN-c and TNF-a expression and increased IL-10 and IL-12p70 production after 7
day low dose skin TLR7 triggering. Additionally, respiratory NK cytotoxic activity was increased after 7d skin TLR7 triggering.
In contrast, lung histology and bronchoalveolar cell counts were not affected suggesting that skin TLR7 stimulation
modulated respiratory leukocyte composition without inducing overt pulmonary inflammation. These data suggest the
possibility to modulate respiratory leukocyte composition and respiratory cytokine responses against pathogens like
Klebsiella pneumonia through skin administration of a clinically approved TLR7 ligand. Skin administration of synthetic TLR7
ligands may represent a novel, noninvasive means to modulate respiratory immunity.
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Introduction
Imiquimod is a synthetic Toll-like receptor TLR7 ligand
stimulating innate and adaptive immunity against viruses and
tumors [1,2]. Clinically, imiquimod cre`me is a FDA-approved
immune response modifier that is indicated for the skin treatment
of actinic keratosis, superficial basal cell carcinoma and external
genital warts [3,4]. Plasmacytoid and myeloid dendritic cells as
well as B cells are the major leukocyte subpopulations expressing
TLR7 [5,6]. TLR7 activation of these professional antigen
presenting cells bridges innate and adaptive immunity through
induction of inflammatory cytokines type I interferon, TNF-a, IL-
12, chemokines and DC migration [7–9]. As a consequence,
TLR7 triggering through imidazoquinolines, such as imiquimod
[10], results in enhanced T helper type 1 (Th1) immune responses
and reduced Th2 immune responses. Interestingly, different
groups demonstrated effectiveness of TLR7 triggering to suppress
allergic airway inflammation in experimental asthma models
suggesting immunomodulatory potential of synthetic TLR7
ligands [11–13]. Low-dose TLR7 stimulation has been reported
to inhibit TLR9-induced IFN-a production in human and mouse
plasmacytoid DC revealing immunoregulatory potential of TLR7
ligands [14]. Accordingly, experimental skin vaccination studies
with imiquimod revealed significant co-induction of T regulatory
cells and IL-10 signalling suppressing the activity of cytotoxic
CD8+ T cells [15].
However, systemic administration of TLR7 ligands has been
associated with chronic immune activation, inflammation and
lymphoid disruption resembling HIV-mediated pathology as well
as systemic endothelial activation raising significant concerns with
respect to drug toxicity and safety [16,17]. Accordingly, systemic
administration of the related imidazoquinoline resiquimod in
chronic HCV-infected patients has been associated with frequent
severe grade adverse events including systemic cytokine induction,
fever, shivering and lymphopenia [18].
Recently, Pasmatzi et al reported that skin administration of
imiquimod induced significant alterations in peripheral blood
lymphocytes of healthy individuals indicating the possibility that
skin TLR7 triggering may represent a novel, less toxic strategy to
modulate systemic immunity [19]. Moreover, repeated skin
administration of imiquimod in mice has been reported to
significantly increase the survival of mice bearing intracranial
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glioma and breast cancer suggesting that skin triggering of TLR7
may result in systemic immunmodulation [20]. Skin administra-
tion of imiquimod (AldaraH creme) as a single agent in tumor-
bearing mice was associated with intracranial elevation of tumor
infiltrating CD4+ T helper and CD8+ T killer lymphocytes [20].
These data suggested the possibility that skin administration of
imiquimod can modulate leukocyte populations in other organs.
In this placebo-controlled study we have analysed for the first
time the hypothesis that skin administration of a synthetic TLR7
ligand may be capable of modulating the composition of
respiratory leukocyte subsets. By means of multiparameter flow
cytometry we have investigated alterations of all major leukocyte
subsets, including dendritic cell (DC) subpopulations (plasmacytoid
DC, monocytic DC, CD103+ DC, CD11bhigh DC) and innate
lymphocyte subsets (natural killer cells, gamma delta TCR positive
lymphocytes). We have included lung DC subsets into the analysis
because they play critical roles as instigators and modulators of
immunity [21,22]. Our results revealed that skin administration of
a synthetic TLR7 ligand applied to the back skin promoted
significant alterations of respiratory monocytic DC, CD11bhigh
DC, NK cells and B cells. Notably, in contrast to modulating
respiratory DC, NK and B cell numbers, skin administration of
imiquimod did not result in overt pulmonary inflammation as
indicated by normal lung histology and normal cell counts in
bronchoalveolar lavage.
Results
Skin TLR7 Stimulation Induces Accumulation of
Respiratory DC in Contrast to Macrophages and
Granulocytes
To assess the effects of skin TLR7 triggering on respiratory
leukocytes, mice were treated with imiquimod creme (AldaraH)
applied to the back skin for up to seven days. To control for
unspecific effects related to drug formulation or treatment
procedure, control animals were treated with placebo cre`me
consisting of identical ingredients except for imiquimod. Sustained
TLR7 skin triggering over 7 days did not affect total respiratory
leukocyte numbers, whereas single exposure resulted in reduced
leukocyte numbers (Fig. 1A).
Analysis of leukocyte populations indicated normal or reduced
absolute numbers of macrophages (CD45+ SiglecF+ F4/80+;
Fig. 1B) and respiratory granulocytes (CD45+; F4/80low/neg;
CD11b++, GR-1++; Fig. 1C). In contrast, both relative and absolute
respiratory DC (CD45+, CD11c+, SiglecFneg, NK1.1neg) numbers
were elevated after sustained skin TLR7 triggering with imiquimod
over 7 days (0.6 mg imiquimod; p,0.001; Fig. 1D). The employed
gating strategy facilitated the distinction of these subsets (Fig. S1).
Within the CD11c+ cells, autofluorescent CD11c+ alveolar macro-
phages were identified based on SiglecF expression and excluded
from the DC analysis (Fig. S1). Absolute respiratory DC numbers
increased 151% after 7 days when compared to placebo-treated
control animals (491322636872 versus 195059615390; Fig. 1D;
p,0.001) suggesting a marked effect of skin TLR7 triggering on
respiratory DC. Accordingly, the DC/Macrophage ratio in lung
tissue markedly increased after 7d skin application of 0.6 mg
imiquimod from 0.7 (60.08) to 1.9 (60.2; p,0.001).
Monocytic DC and CD11bhigh DC Represented the Major
Respiratory DC Subsets Increased after Skin TLR7
Triggering
In order to determine which specific DC subset is elevated after
skin TLR7 administration we performed 8-colour flow cytometry
and quantitated plasmacytoid DC, CD103+ DC, monocytic DC
and CD11bhigh DC. Dissection of the four major DC subsets was
performed based on expression of 120g8, CD103, CD11b and
MHC-class II (I-Ab; Fig. S2). DC subset analysis revealed that
monocytic DC represented the principle DC subpopulation
increased after topical TLR7 triggering (Fig. 2A). Relative
monocytic DC frequencies increased from 2–3% of all CD45+
respiratory leukocytes to $10% in 0.6 mg imiquimod-treated
mice (p,0.001; Fig. 2A). Interestingly, significant elevation of
respiratory monocytic DC was detectable already after 24 h
(p,0.001) suggesting that a single imiquimod dose is sufficient to
elevate respiratory monocytic DC (Fig. 2A). Additionally, relative
and absolute CD11bhigh DC numbers were also elevated after
sustained skin TLR7 application over 7 days (Fig. 2A). In contrast,
pDC and CD103+ DC were not or only moderately affected.
Given the fact that skin TLR7 triggering changed both absolute
DC numbers and relative DC subsets in the lung we next
questioned how imiquimod affected the composition of the DC
compartment in the lung. In comparison to placebo-treated mice,
imiquimod significantly increased the monocytic DC frequency
among all respiratory DC from 42–44% up to 70–78% (Fig; 2B
p,0.001). Interestingly, modulation of respiratory DC composi-
tion was detectable within 24 h. Relative DC composition of d1
and d7 placebo-exposed mice were almost identical indicating that
DC composition was not affected by the placebo treatment
(Fig. 2B).
Skin TLR7 Triggering Modulates Expression of
Costimulatory and Inhibitory Molecules on Respiratory
DC
Analysis of costimulatory molecule (CD40, CD80, CD86) and
regulatory B7 family member (CD274, CD275) expression
indicated that skin TLR7 triggering affected surface expression
of respiratory DC. On pDC, CD40, CD86 and CD274 expression
was increased in comparison to placebo controls (Fig. 3).
Interestingly, expression of the regulatory B7 family member
CD274 was markedly increased on pDC, CD103+ DC and
CD11bhigh DC after skin TLR7 triggering (Fig. 3).
Reduction of Respiratory B Lymphocytes and Elevation of
Respiratory Natural Killer Cell Numbers after Skin
Imiquimod Exposure
Classical T and B lymphocyte populations, NK cells and cd
TCR+ T cells were gated according to conserved surface markers
whereas T regulatory CD4+ T cells were identified after
intracellular FoxP3 staining (Fig. S3). Analysis of lymphocyte
subpopulations revealed a temporary reduction of absolute CD3+
T cells including CD4+ T helper and CD8+ T killer cells after 1d
imiquimod exposure, whereas respiratory CD3+ T cell numbers
were not affected after 7d imiquimod exposure (Fig. 4A, B). In
contrast, relative and absolute CD19+ B cell numbers were
significantly reduced both after 1d and 7d drug exposure
suggesting a marked effect of skin imiquimod on respiratory B
lymphocytes (Fig. 4A, B). In contrast, sustained skin imiquimod
exposure over 7 days significantly increased relative and absolute
numbers of respiratory NK cells (Fig. 5A, B) suggesting an effect of
imiquimod on innate lymphocytes. After 7 days of skin TLR7
triggering, absolute numbers of respiratory NK cells increased
from 195856 (614504) to 458312 (639096) per lung preparation
(p,0.001; Fig. 5B). Interestingly, functional analysis of cytotoxic
activity of equal numbers of magnetic bead-enriched respiratory
NK cells indicated increased cytotoxic activity of 7d imiquimod
exposed animals suggesting that sustained skin TLR7 triggering
Skin TLR7 and Lung Dendritic Cells
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Figure 1. Skin application of imiquimod increases relative and absolute respiratory DC numbers. Skin of mice was treated with TLR7
ligand imiquimod or placebo in a daily fashion and relative and absolute respiratory leukocyte subsets were quantitated by flow cytometry at the
indicated time points (see gating stategy in Fig. S1). Total lung leukocytes (A), respiratory macrophages (B), respiratory granulocytes (C) and
respiratory DC numbers after imiquimod exposure (D). Mean 6 SEM; n $4; *p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g001
Skin TLR7 and Lung Dendritic Cells
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may promote respiratory NK activity (Fig. 5C). Skin imiquimod
application affected also respiratory cd TCR+ CD3 T cells and to
a lesser extent CD4+CD25+Foxp3+ T regulatory cells, but these
differences were statistically not significant (Fig. 5A, B).
Topical TLR7 Triggering Affects Respiratory Cytokine
Production
Having established that skin TLR7 triggering can modulate
respiratory leukocyte numbers we questioned whether cytokine
production (IFN-c; IL-2; IL-10, IL-12p70, IL-23, TNF-a) was also
affected. Accordingly, equal numbers of CD45+ microbead-
purified respiratory leukocytes were stimulated via TLR4 with
LPS and via TLR9 with CpG oligonucleotides. Moreover, to
analyse the cytokine response against a typical respiratory
pathogen, leukocytes were also stimulated with Klebsiella pneu-
monia lysate. Results revealed that IFN-c was significantly
reduced in d1 and d7 animals after LPS, CpG and Klebsiella
lysate stimulation (Fig. 6). With respect to TNF-a and IL-10, d7
animals showed a trend towards decreased TNF-a and increased
IL-10 production after low dose imiquimod exposure in contrast to
d1 animals (Fig. 6). IL-23 was below the detection limit and IL-2
production did not differ between the groups. IL-12p70 was only
detectable after Klebsiella pneumonia stimulation and exhibited
elevated levels in imiquimod-exposed animals. In summary the
results indicate the possibility that skin TLR7 triggering may
promote a respiratory cytokine response being characterized as
decreased IFN-c, decreased TNF-a, increased IL-10 and in-
creased IL-12p70.
Modulation of Respiratory Leukocyte Numbers after Skin
TLR7 Triggering is Associated with Peripheral Blood
Changes
Since respiratory leukocytes are repopulated through the
peripheral blood we analyzed changes in major blood leukocyte
subsets after skin TLR7 administration. Results indicated that
peripheral blood DC, B lymphocytes and natural killer cells
exhibited similar changes after skin TLR7 administration suggest-
ing a direct association of peripheral blood changes with
respiratory leukocyte subsets after skin imiquimod exposure
(Fig. 7).
Topical TLR7 Triggering does not Induce a
Bronchoalveolar Inflammatory Response
The marked modulation of respiratory leukocyte composition
raised the question whether sustained skin TLR7 triggering has
induced signs of pulmonary inflammation. Accordingly, lungs of
sacrificed animals were analysed in a blinded manner by
pathology and leukocyte numbers after bronchoalveolar lavage
were quantitated. Lung histology indicated no signs of pathology;
in fact lungs from imiquimod exposed d1 and d7 animals were not
Figure 2. Accumulation of respiratory DC after skin TLR7 triggering is caused by an increase of monocytic DC and CD11bhigh DC
subsets. Modulation of respiratory DC subsets pDC, CD103+ DC, monocytic DC and CD11bhigh DC (see gating strategy in Fig. S2) after skin
imiquimod exposure versus placebo as described in materials and methods (A, B). Mean 6 SEM; n $4; *p,0.05; **p,0.01; ***p,0.001 versus
placebo.
doi:10.1371/journal.pone.0043320.g002
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different from placebo-exposed animals (Fig. 8A; Fig. S5).
Accordingly, leukocyte numbers after bronchoalveolar lavage
were not affected in comparison to placebo-exposed controls
(Fig. 8B). These results are in agreement with the total respiratory
leukocyte numbers in lung homogenate (Fig. 1A) and indicate that
skin TLR7 ligand administration was not inducing pulmonary
inflammation.
Topical TLR7 Triggering Modulates Skin Dendritic Cell
CD86 and CD274 Expression
CD11c+ MHC-class II+ skin DC subsets were discriminated
into Langerhans cells and dermal dendritic cell subsets according
to CD207 (langerin), CD103 and CD11b expression (Fig. S4).
Results indicated no significant changes in absolute DC subset
numbers after skin imiquimod exposure. However, in contrast,
analysis of DC maturation status indicated significant upregulation
of CD86 and CD274 surface expression in most skin DC subsets,
already after 1d skin imiquimod exposure (Fig. 9). These results
suggested that topical skin TLR7 triggering affected maturation of
skin DC.
Discussion
Here we presented the results of a placebo-controlled animal
study investigating the modulation of respiratory leukocyte subset
numbers after skin administration of the TLR7 ligand imiquimod.
Results revealed the possibility to modulate respiratory leukocyte
composition after skin TLR7 triggering without inducing pulmo-
nary inflammation as indicated by normal histopathology and
BAL counts. Skin TLR7 triggering markedly elevated absolute
and relative respiratory DC and respiratory natural killer cell
numbers and reduced respiratory B cell numbers. Notably, most of
the changes were already detectable within 24 h and sustained
skin TLR7 triggering over 7 days further enhanced the effects.
The results are specifically related to TLR7 triggering since
control animals receiving placebo cre`me exhibited no changes.
Additionally, skin TLR7 triggering also modulated cytokine
production of respiratory leukocytes as indicated by reduced
TNF-a and increased IL-10 production.
So far, the effects of TLR7 stimulation have been primarily
studied with respect to peripheral blood and lymphoid tissue
changes but the modulation of respiratory leukocytes after skin TLR7
Figure 3. Expression of costimulatory and regulatory surface moelcules on respiratory DC subsets after skin TLR7 triggering.
Surface expression of CD40, CD80, CD86, CD274 and CD275 on respiratory DC subsets after 1d and 7d skin imiquimod exposure versus placebo.
Respiratory DC subsets were gated as described in Fig. S2. Mean expression 6 SEM; n $3; *p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g003
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Figure 4. Respiratory T and B lymphocyte numbers are suppressed after skin TLR7 stimulaton. Relative (A) and absolute (B) respiratory T
and B lymphocyte subsets were quantitated by flow cytometry (see gating strategy Fig. S3) after skin imiquimod treatement. Mean 6 SEM; n $4;
*p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g004
Skin TLR7 and Lung Dendritic Cells
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triggering has been unknown. Gunzer and colleagues reported
that a single systemic dose of the TLR7 ligand R848 resulted in a
transient depletion of peripheral blood leukocytes due to increased
endothelial adhesiveness [16]. In agreement, we also observed a
reduction of peripheral blood B lymphocytes, T lymphocytes and
monocytes after one day skin imiquimod exposure.
However, the smaller leukocyte subsets of NK cells and DC
were increased already after one day imiquimod exposure.
Sustained systemic exposure to TLR7 ligands over 7 days has
been reported to induce a chronic inflammatory condition in the
murine lymphoid system and disruption of the lymphoid structure
[17]. Accordingly, we have analyzed the histology of lung tissue
sections after 7 day skin TLR7 agonist exposure and did not find
any signs of pulmonary inflammation. The absence of lung
pathology after 7 day imiquimod exposure, associated with normal
total respiratory leukocyte and BAL numbers suggested that skin
imiquimod application did not induce a chronic respiratory
inflammation. Rather, the results indicated that skin imiquimod
application modulated the composition of respiratory leukocytes as
well as the cytokine producing capacity. Interstingly, recently it
was reported that intranasal administration of the related TLR7
ligand resiquimod did also induce transient accumulation of
respiratory NK, DC and granulocytes [13]. Our results extend
these findings and suggest that skin TLR7 ligand administration is
able to modulate the leukocyte composition of the lungs.
It can be argued that the applied imiquimod doses in the
discussed experimental studies are higher than those used in the
clinical situation. However, recently it was reported that sustained
skin application of imiquimod to humans significantly modulated
peripheral blood lymphocyte numbers when compared to sex-and
age-matched controls receiving vehicle [19]. These results support
the hypothesis that skin TLR7 ligand application principally is
able to modulate systemic leukocyte numbers. Additionally,
repeated skin administration of imiquimod in mice has been
reported to significantly improve the survival of animals bearing
intracranial tumors [20] supporting the concept of systemic
Figure 5. Respiratory NK cell numbers are increased after skin TLR7 triggering. Relative (A) and absolute (B) respiratory NK cells, cd T
lymphocytes and CD4+CD25+Foxp3+T regulatory cells were quantitated by flow cytometry (see gating strategy Fig. S3) after skin imiquimod
treatement. Cytotoxicity (C) of equal numbers of magnetic bead enriched respiratory NK cells were determined against Yac-1 target cells after 1d and
7d imiquimod exposure. Mean 6 SEM; n $4; *p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g005
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immunomodulation after skin TLR7 triggering. In agreement with
this concept, we did find significant modulation of respiratory
leukocyte cytokine production capacity even at low imiquimod
doses (0.12 mg/d) that did exert no or only minor effects on
respiratory leukocyte numbers. Respiratory leukocytes of animals
receiving 0.12 mg imiquimod for seven days produced signifi-
cantly less TNF-a and IFN-c, both after LPS, CpG and Klebsiella
pneumonia lysate stimulation when compared to placebo-exposed
controls. These results suggested that modulation of leukocyte
cytokine production capacity can be detected at lower doses than
modulation of leukocyte numbers after skin TLR7 ligand
application. Interestingly, Klebsiella pneumonia lysate stimulated
respiratory leukocytes of animals receiving low dose skin TLR7
triggering over 7 days produced significantly higher amounts of
immunosuppressive IL-10 and IL-12p70. Moreover, analysis of
respiratory DC surface markers and respiratory NK cell cytotoxic
activity suggested that skin imiquimod exposure modulated
additional functional variables of respiratory leukocytes.
These results suggested the possibility that sustained skin TLR7
triggering may promote respiratory immunoregulation. In agree-
ment with this hypothesis, it was shown that topical imiquimod
therapy in a murine breast cancer model was associated with high
IL-10 levels and IL-10 blockade markedly improved antitumor
activity of imiquimod [23].
In summary, the presented placebo-controlled animal study
showed that skin TLR7 triggering with imiquimod modulated
respiratory DC and NK cell numbers as well as respiratory
cytokine production capacity. Modulation of respiratory leuko-
cytes was not associated with signs of pulmonary inflammation
indicating the possibility that skin TLR7 triggering may represent
a novel non-invasive means to modulate respiratory immune
responses. Although this study was not designed to investigate the
molecular mechanism of elevation of respiratory DC and NK cells,
the results reveal novel insight into the in vivo activity of
imiquimod. Additional studies are needed to dissect the molecular
pathways involved in respiratory immunomodulation after skin
TLR7 triggering.
Materials and Methods
Ethics, Mice and Treatment
Animal experiments were performed after approval of the ethics
authority board Regierungspra¨sidium Gießen Hessen (file #29/
2009). Specific-pathogen-free C57BL/6 (C57BL/6NCrl) mice,
Figure 6. Skin TLR7 triggering modulates respiratory cytokine production. Respiratory leukocytes were CD45+ microbead purified from 1d
and 7d imiquimod or placebo-treated animals and IFN-c (A), TNF-a (B), IL-10 (C), IL-2 (D), IL-12p70 (E) and IL-23 were quantitated after LPS, CpG or
Klebsiella pneumonia lysate stimulation. IL-23 was below the detection limit (27 pg/ml) in all groups. In unstimulated cells, cytokines were not
detectable (detection limit 27 pg/ml). Mean 6 SEM; n $3; *p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g006
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10–12 weeks of age were purchased from Charles River, Sulzfeld,
Germany and maintained under specific-pathogen-free conditions.
0.12–0.6 mg/d imiquimod (AldaraH 5% cre`me; Meda Pharma,
Germany) were applied for 1–7 days to the shaved back skin of
sedated animals. Shaving of a 2 cm2 back neck skin area per mice
was done after anesthesia with xylazoline hydrochloride (Bayer,
Germany). Back neck skin was selected as application area,
because it prevented licking off the drug by the animals.
Imiquimod (0.12 mg, 0.6 mg) was applied with a pipet directly
onto the shaved skin and it was waited 1–2 min until the drug was
absorbed into the skin. In long term treated animals, repeated
applications were done after isofluorane anesthesia. Control
animals were treated in a manner identical except they received
placebo creme (provided by Meda Pharma) instead of imiquimod
creme. After drug or placebo application, animals were separated
into single cages until the end of the experiment.
Lung Preparation and Histology
Lung single cell suspension were prepared after enzymatic
digestion as described in detail [24] with minor modifications.
Briefly, mice were euthanized and lungs were perfused via the right
ventricle with HBSS (PAA, Germany) to remove the intravascular
pool of cells. Tissues were minced and digestion was performed in
0.09 U/ml type A collagenase (Roche, Germany) and 9.09 U/ml
DNase (Roche, Germany) in IMDM (PAA, Germany) with 10%
FCS (PAA, Germany) at 37uC for 1h. Single cell suspension were
prepared by tissue resuspension with 20 G 1 K canules
(0.9640 mm; BD, Germany) and by mashing through a 70 mM
cell strainer (BD, Germany). Red blood cells were lysed by
ammoniumchloride lysis. Cells were washed with HBSS for flow
cytometry staining or leukocytes were magnetic-bead sorted after
washing with PBS/2% BSA/2 mM EDTA (PAA, Germany).
Bronchoalveolar lavages (BAL) were performed as described [25].
Lung (tissue) samples were fixed in 10% formalin and routinely
embedded in paraffin. Sections were cut at 5 mm thickness,
dewaxed and stained with hematoxylin and eosin (H&E).
Flow Cytometry
Cellular phenotyping was performed on a FACS CantoII flow
cytometer (Becton Dickinson, San Jose, CA, USA) as described
[26] with minor modifications. The following fluorochrome-
labelled monoclonal antibodies conjugated to FITC, PE, PE-
TxR, PeCy7, PerCPCy5.5, APC, APC-Cy7, Pacific Blue and
appropriate isotype controls were used for surface staining
according to the manufacturer’s instructions: CD3e, CD4,
CD8a, CD11b, CD11c, CD19, CD25, CD45, NK1.1, CD90,
CD103, TCR-cd, I-Ab, GR1, F4/80, CD40, CD80, CD86,
CD274, CD275 (all mabs from Biolegend, Germany), Siglec-F
(BD Biosciences, Germany), Langerin (CD207; 929F301, Im-
genex, SanDiego, USA) and 120g8 (Dendritics, France). Intracel-
lular Foxp3 staining was performed with the Foxp3 staining set
(eBiosciences, Germany) according to the manufacturer instruc-
tions. Absolute leukocyte numbers were determined by using
trucount beads (Becton Dickinson, Germany) according to the
manufacturer instructions.
Figure 7. Respiratory leukocyte subset changes are associated with modulation of corresponding peripheral blood leukocyte
subsets. Peripheral blood leukocyte subsets were quantitated by flow cytometry after skin imiquimod exposure. Mean/ul 6 SEM; n $3; *p,0.05;
**p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g007
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Skin Cell Preparation and DC Analysis
Skin cells were prepared as described [27] with minor
modifications. Briefly, pieces of skin were removed and subcuta-
neous fat was removed with forceps. Skin pieces were digested for
45 min at 37 C with 3 ml digestion cocktail. Digestion cocktails
contains collagenase XI (4129 U/ml; Sigma, Germany, #C9407-
100 mg); hyaluronidase (260 U/ml; Sigma, #H3506-100 mg) and
DNase (0.1 mg/ml, Roche) diluted in RPMI 1640 with L-
glutamine (PAA Laboratories), penicillin/streptomycin (PAN
Biotech) and 10% heat inactivated FCS (PAA Laboratories).
Digested skin was minced and washed twice with ice-cold medium
with 10 mM EDTA and filtered through a 70 mM cell strainer
(BD, Germany). Skin DC were identified by flow cytometry after
gating for CD45+; MHC-class II+ (I-Ab) and CD11c+ cells.
Subsequently, Langerhans cells (LC) and dermal dendritic cells
(DDC) subsets were dissected based on CD207, CD11b and
CD103 expression according to Henri et al. [28].
Cytokine Quantification
26105 respiratory leukocytes were bead-purified with CD45
microbeads (Miltenyi Biotec, Germany) according to the manu-
facturer instruction. Cells were stimulated in 96-well plates
(Greiner, Germany) with LPS (1 mg/ml; 0111:B4 strain, Sigma
Aldrich, Germany), or CpG ODN 1826 (Invivogen, France) for
24 h in RPMI 1640 medium supplemented with L-glutamine,
penicillin/streptomycin, 10% heat-inactivated FCS (PAA Ger-
many). Klebsiella pneumonia lysate (Serotype 2, ATCC 43816)
was prepared after overnight suspension culture. Bacteria were
concentrated after centrifugation (15 min, 1000 g), diluted in 5 ml
0.9% NaCl, heated for 15 min.at 65uC in a water bath and used at
10 ml/ml for stimulation experiments. Mouse IFN-c, TNF-a, IL-2,
IL-10, IL-12p70 and IL-23 were quantitated by cytometric bead
array (flow cytomix, eBioscience, Germany).
Natural Killer Cytotoxicity Assay
Flow cytometry cytotoxicity assay was performed according to
the principles described by Kane et al. [29]. Respiratory effector
NK cells were enriched using CD49b microbeads according to
manufacturer instructions (Miltenyi Biotec, Bergisch-Gladbach,
Germany). Effector cells were incubated at the indicated effector/
target (E/T) ratios in culture medium with carboxyfluorescein
diacetate succinimidyl ester (CFDA-SE) labeled Yac-1 target cells
(Cell line Service, Eppelheim, Germany; 26104/well) in 96 well
round bottom wells (Greiner) for 8 h. Culture medium consisted of
Figure 8. Skin TLR7 stimulation does not induce lung histopathology or alveolar leukocytosis. Lung sections (A) and BAL leukocyte
numbers (B) of mice exposed to imiquimod or placebo. (A) shows histopathology of d7 animals. Histopathology of d1 animals exhibited similar
results (Fig. S5). BAL leukocyte numbers from d1 and d7 treated animals after imiquimod exposure (B). Mean 6 SEM; n $3.
doi:10.1371/journal.pone.0043320.g008
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RPMI 1640 with L-glutamine (PAA Laboratories), penicillin/
streptomycin (PAN Biotech) and 10% heat inactivated FCS (PAA
Laboratories). Molar CFDA-SE labeling concentration of target
cells was 1 mm and was performed according to the manufacturer
instructions (Vybrant CFDA-Cell Tracer kit, Molecular probes,
Eugene, USA). Dead cells were quantitated by flow cytometry
after adding Sytox Blue (Invitrogen, Germany). Percent lysis was
calculated as follow: Percent lysis = Percent dead Yac-1 cells:
(CFDA+ Sytox+ double positive cells/CFDA+ cells)6100. Spon-
taneous lysis was determined in control YAC-1 cultures without
NK effectors and was substracted from the actual lysis. Sponta-
neous lysis was consistently lower than 5%.
Statistical Analyses
Data are shown as means and SEM. Statistical analyses were
performed with Prism 5.02 software (Graphpad software, Inc.).
The significance of differences between groups were analysed by
one-way ANOVA with Tukey’s post-hoc -test for multiple
comparisons. A p-value ,0.05 was considered significant.
Supporting Information
Figure S1 Flow-cytometry based identification of respi-
ratory macrophages, granulocytes and DC (A-C). Leuko-
cytes in lung cell suspensions were identified as CD45+ cells.
Among the CD45+ respiratory leukocytes, macrophages were
identified based on Siglec-F and F4/80 expression (A). Respiratory
granulocytes were identified as CD45+ cells, F4/80low-neg and
CD11b++ GR-1++ (B). Respiratory DC were identified within the
CD45+ cells after gating first for the CD11c+ Siglec-Fneg cells to
exclude highly autofluorescent alveolar macrophages. Subsequent-
ly, among the remaining cells, NK1.1++ NK cells were gated out to
precisely identify respiratory DC (C). Representative gating of
n.10 experiments.
(TIF)
Figure S2 Gating strategy for discrimination of respi-
ratory DC subsets. Respiratory DC were further
dissected based on 120g8; CD103, CD11b and I-Ab
(MHC-class II) expression. Among the respiratory DC
fraction, plasmacytoid DC were identified based on 120g8+
CD11bneg expression. Out of the non-plasmacytoid DC fraction;
CD103+ DC were identified based on CD103 and MHC-class II
expression. The remaining respiratory DC were examined for
CD11b and MHC-class II (I-Ab) expression dividing them into two
major groups: monocytic DC (CD11b++, MHC-class IIlow,
CD103neg, 120g8neg NK1.1low, Siglec Fneg, CD11c+; CD45+)
and CD11bhi DC (CD11b++, MHC-IIhigh, CD103neg, 120g8neg
NK1.1low, Siglec Fneg, CD11c+; CD45+). Representative gating of
n.10 experiments.
(TIF)
Figure S3 Gating strategy for discrimination of respi-
ratory lymphocyte subpopulations (A) and regulatory T
cells (B). First, classical CD3+ T cells and CD19+ B cells were
identified within the CD45+ SSClow respiratory leukocytes, Out of
the CD3+ T cell fraction, respiratory T helper and T killer cells
were identified based on CD4 and CD8 expression, respectively
(A). Additionally, among the CD45+ SSClow fraction, respiratory
NK cells were identified as CD3neg NK1.1+ cells and cd T cells
were identified as CD3+ cd TCR+ cells (A). Respiratory T
regulatory cells were identified within the CD45+ SSClow fraction
as CD4+CD25+ cells and then examined for Foxp3 expression (B).
Foxp3 gates were set according to control staining with identical
mabs except for Foxp3 isotype-matched control (so-called
Figure 9. Topical TLR7 triggering affects skin dendritic cell CD86 and CD274 expression. Absolute skin DC subset numbers from 2cm2
skin (A) and subset specific expression of CD86 (B) and CD274 (C) were determined by flow cytometry after 1d and 7d imiquimod exposure as
described in the Materials and Methods. Among the CD11c+ MHC-class II+ CD45+ skin DC, Langerhans cells (LC) were identified based on CD207+,
CD103-, CD11bint expression profile. Different dermal DC (DDC) subsets were discriminated based on heterogenous expression of CD207, CD103,
CD11b. Mean 6 SEM; n $2-3. *p,0.05; **p,0.01; ***p,0.001 versus placebo.
doi:10.1371/journal.pone.0043320.g009
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fluorescence minus 1 control; B). Representative gating of n.10
experiments.
(TIF)
Figure S4 Gating strategy for discrimination of skin DC
subpopulations. Skin DC were identified by flow cytometry
after gating for CD45+, CD11c+ and MHC-class-II+ cells (I-Ab+).
Subsequently, Langerhans cells (LC) and dermal dendritic cell
subsets (DDC) were dissected based on CD207 (langerin), CD103
and CD11b expression. LC were identified as CD207+, CD103-
cells. DDC were dissected into CD207+ CD103+, CD207- CD11b-
and CD207- CD11b+ subsets. Representative gating of n.10
experiments.
(TIF)
Figure S5 Lung histopathology of d1 animals. Lung
sections of d1 mice exposed to imiquimod or placebo. Mean 6
SEM; n $3.
(TIF)
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